Niro Okimoto, Kenji Yamato, Yoshihiro Honda, Takeyuki Kurihara, Kohichi Osaki, Naoko Asaoka, Kazue Fujita, Hideo Ohba
The effect of intravenous ciprofloxacin (CPFX) on hospital-acquired pneumonia was examined. The subjects were 32 patients with hospital-acquired pneumonia classified as being in group I, group II, and group III, based on The Japanese Respiratory Society Guidelines for management of hospital-acquired pneumonia. None of the patients had received antibiotic treatment for the pneumonia. CPFX 300 mg was intravenously infused twice daily for 3-14 days, and its clinical effect, bacterological effect, and side effects were examined...
February 2005: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy